![](/img/cover-not-exists.png)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, Iouri Ivanov, Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti, Doris M. BenbrookVolume:
119
Year:
2010
Language:
english
Pages:
7
DOI:
10.1016/j.ygyno.2010.08.002
File:
PDF, 490 KB
english, 2010